Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

What We're Reading

  • What We're Reading
    A Sampling of Highlights from the Literature
    Cancer Immunol Res June 1 2020 8 (6) 723-723;

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Human NKp44+ Group 3 Innate Lymphoid Cells Associate with Tumor-Associated Tertiary Lymphoid Structures in Colorectal Cancer
    Atsuyo Ikeda, Takayuki Ogino, Hisako Kayama, Daisuke Okuzaki, Junichi Nishimura, Shiki Fujino, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Chu Matsuda, Hirofumi Yamamoto, Kiyoshi Takeda, Tsunekazu Mizushima, Masaki Mori and Yuichiro Doki
    Cancer Immunol Res June 1 2020 8 (6) 724-731; DOI:10.1158/2326-6066.CIR-19-0775

    Innate lymphoid cells (ILCs) are strategic players in immune responses. Group 3 ILCs (ILC3s) are found in CRC tissue associated with tertiary lymphoid structures (TLSs). Both TLSs and ILCs decrease during CRC progression, suggesting an unsuspected relationship.

Research Articles

  • Research Articles | AuthorChoice
    Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
    Dinali Wijewarnasuriya, Christina Bebernitz, Andrea V. Lopez, Sarwish Rafiq and Renier J. Brentjens
    Cancer Immunol Res June 1 2020 8 (6) 732-742; DOI:10.1158/2326-6066.CIR-19-0908

    CAR T cells can be driven into a dysfunctional state through excessive costimulation. Understanding the limits of costimulation for CAR T cells will aid design of more efficacious CAR T cells for future clinical trials.

  • Research Articles | AuthorChoice
    Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy
    Dylan J. Drakes, Sarwish Rafiq, Terence J. Purdon, Andrea V. Lopez, Smita S. Chandran, Christopher A. Klebanoff and Renier J. Brentjens
    Cancer Immunol Res June 1 2020 8 (6) 743-755; DOI:10.1158/2326-6066.CIR-19-0910

    Tumor-directed T cells function better when expressing IL18 rather than IL12. TCR-modified T cells secreting IL18 eradicate established tumors in syngeneic models in combination with sublethal irradiation and in xenograft models, providing evidence to support IL18-boosted T-cell clinical trials.

  • Research Articles
    Donor Lymphocyte–Derived Natural Killer Cells Control MHC Class I–Negative Melanoma
    Nana Dang, Yuan Lin, Mark Waer and Ben Sprangers
    Cancer Immunol Res June 1 2020 8 (6) 756-768; DOI:10.1158/2326-6066.CIR-19-0666

    Donor lymphocyte infusion after allogenic bone marrow transplantation can promote antitumor immunity but risks graft-versus-host disease. If there is no prior marrow transplantation, then donor lymphocyte infusion allows donor NK cells to control MHC-negative melanoma without toxicity.

  • Research Articles
    Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity against Tumors Resistant to Cytotoxic T Cells
    Lucas Ferrari de Andrade, Sushil Kumar, Adrienne M. Luoma, Yoshinaga Ito, Pedro Henrique Alves da Silva, Deng Pan, Jason W. Pyrdol, Charles H. Yoon and Kai W. Wucherpfennig
    Cancer Immunol Res June 1 2020 8 (6) 769-780; DOI:10.1158/2326-6066.CIR-19-0483

    Tumor cells evade NK-cell–mediated immunity by proteolytic shedding of the activating MICA/B ligands. Use of a MICA/B antibody inhibits MICA/B proteolytic shedding, leading to NK-cell responses against tumor cells resistant to cytotoxic T cells.

  • Research Articles | AuthorChoice
    CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement
    Miguel Gaspar, John Pravin, Leonor Rodrigues, Sandra Uhlenbroich, Katy L. Everett, Francisca Wollerton, Michelle Morrow, Mihriban Tuna and Neil Brewis
    Cancer Immunol Res June 1 2020 8 (6) 781-793; DOI:10.1158/2326-6066.CIR-19-0798

    Antibody agonists that target T-cell costimulatory pathways are being tested in the clinic. FS120, a dual agonist antibody specific for CD137 and OX40, delays tumor growth by improving the activation and proliferation of peripheral T cells.

  • Research Articles
    Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells
    Junmei Wang, Farah Hasan, Amanda C. Frey, Haiyan S. Li, Jungsun Park, Ke Pan, Cara Haymaker, Chantale Bernatchez, Dean A. Lee, Stephanie S. Watowich and Cassian Yee
    Cancer Immunol Res June 1 2020 8 (6) 794-805; DOI:10.1158/2326-6066.CIR-19-0619

    Improving the in vivo persistence of adoptive cell therapies correlates to better patient responses. Histone deacetylase inhibitors and IL21 shift CD8+ T cells to a more persistent, central memory phenotype by increasing CD28 promoter accessibility.

  • Research Articles
    Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
    Patricia E. de Almeida, Judy Mak, Genevive Hernandez, Rajiv Jesudason, Aurelie Herault, Vincent Javinal, Jovencio Borneo, Jeong M. Kim and Kevin B. Walsh
    Cancer Immunol Res June 1 2020 8 (6) 806-818; DOI:10.1158/2326-6066.CIR-19-0360

    Amplification of tumor hypoxia by anti-VEGF treatment enhances CD8+ T-cell antitumor responses through increased HIF1α activity. Combining anti-angiogenics and immunotherapeutics may be useful for the treatment of cancer.

  • Research Articles
    Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils
    ANM Nazmul H. Khan, Tiffany R. Emmons, Jerry T. Wong, Emad Alqassim, Kelly L. Singel, Jaron Mark, Brandon E. Smith, Joseph D. Tario, Kevin H. Eng, Kirsten B. Moysich, Kunle Odunsi, Scott I. Abrams and Brahm H. Segal
    Cancer Immunol Res June 1 2020 8 (6) 819-828; DOI:10.1158/2326-6066.CIR-19-0556

    A substantial proportion of cells with early-stage myeloid-derived suppressor cell (e-MDSC) surface markers in circulation and in ascites of patients with ovarian cancer are basophils. Exclusion of basophils from e-MDSC is required for prognostic and therapeutic studies.

  • Research Articles
    CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis
    Silvia Lonardi, Sara Scutera, Sara Licini, Luisa Lorenzi, Anna Maria Cesinaro, Luisa Benerini Gatta, Carlotta Castagnoli, Daniele Bollero, Rosaria Sparti, Michela Tomaselli, Daniela Medicina, Federica Calzetti, Marco Antonio Cassatella, Fabio Facchetti, Tiziana Musso and William Vermi
    Cancer Immunol Res June 1 2020 8 (6) 829-841; DOI:10.1158/2326-6066.CIR-19-0232

    CSF1R promotes efficient Langerhans cell (LC) differentiation from hematopoietic progenitors and migration, which may be reduced by CSF1R kinase inhibition. CSF1R expression in clinical LC histiocytosis (LCH) specimens suggests potential for CSF1R blockade in the treatment of LCH.

Correction

  • Correction | Free Article
    Correction: Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
    Cancer Immunol Res June 1 2020 8 (6) 842-842; DOI:10.1158/2326-6066.CIR-20-0242

Back to top
PreviousNext
Cancer Immunology Research: 8 (6)
June 2020
Volume 8, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • What We're Reading
  • Cancer Immunology Miniatures
  • Research Articles
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement